We are excited to release the digital event agenda for the 1st JAK Inhibitors Drug Development Summit, taking place from the comfort of your own home on Wednesday, June 24.
Join the first multi-disciplinary discussion with large pharma, biotech and academic leaders sharing insights to transform JAK inhibitor clinical development strategies into best and first-in-class approaches for patients in need.
With numerous clinical JAK inhibitor candidates demonstrating genuine viability across oncology, dermatology and autoimmune disease, challenges remain in optimizing the selectivity, safety and efficacy of the next generation of superior JAK inhibitors.
With 16 world-class speakers sharing their latest findings, join those who are overcoming these challenges in this virtual meeting:
- Anabela Cardoso, Global Brand Development Lead, Immunology, Eli Lilly
- Barbara Klencke, Chief Development Officer, Sierra Oncology
- Kimberly McHale, Director, Non-Clinical Science And Development, Dermavant
- Ruben Mesa, Director, UT Health San Antonio MD Anderson Cancer Center
- Piet Wigerinck, Chief Scientific Officer, Galapagos
- Brett King, Associate Professor of Dermatology, Yale School of Medicine
- Maciej Wieczorek, Chief Executive Officer, Celon Pharma
- Brian Kim, Associate Professor And Founder/Chief Scientific Officer, Washington University And Nuogen Pharma
These are only some of the senior experts confirmed to present. With strictly limited places, click here to register your pass for the meeting.
With many clinical challenges to overcome in realizing the full potential of JAK inhibitor utility, join the JAK Inhibitors Drug Development Summit - the only multi-disciplinary and clinical focused digital conference, dedicated to optimizing selectivity, efficacy and safety of the next generation of superior JAK inhibitors across oncology, dermatology and autoimmune diseases. Download the full program here: https://ter.li/quu9dc
Join the first multi-disciplinary discussion with large pharma, biotech and academic leaders sharing insights to transform JAK inhibitor clinical development strategies into best and first-in-class approaches for patients in need.
With numerous clinical JAK inhibitor candidates demonstrating genuine viability across oncology, dermatology and autoimmune disease, challenges remain in optimizing the selectivity, safety and efficacy of the next generation of superior JAK inhibitors.
With 16 world-class speakers sharing their latest findings, join those who are overcoming these challenges in this virtual meeting:
- Anabela Cardoso, Global Brand Development Lead, Immunology, Eli Lilly
- Barbara Klencke, Chief Development Officer, Sierra Oncology
- Kimberly McHale, Director, Non-Clinical Science And Development, Dermavant
- Ruben Mesa, Director, UT Health San Antonio MD Anderson Cancer Center
- Piet Wigerinck, Chief Scientific Officer, Galapagos
- Brett King, Associate Professor of Dermatology, Yale School of Medicine
- Maciej Wieczorek, Chief Executive Officer, Celon Pharma
- Brian Kim, Associate Professor And Founder/Chief Scientific Officer, Washington University And Nuogen Pharma
These are only some of the senior experts confirmed to present. With strictly limited places, click here to register your pass for the meeting.
With many clinical challenges to overcome in realizing the full potential of JAK inhibitor utility, join the JAK Inhibitors Drug Development Summit - the only multi-disciplinary and clinical focused digital conference, dedicated to optimizing selectivity, efficacy and safety of the next generation of superior JAK inhibitors across oncology, dermatology and autoimmune diseases. Download the full program here: https://ter.li/quu9dc
